• 1
    Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodwos R, Trautmann M. A comparison of twice daily exenetide and biphasic insulin as part in patients with type 2 diabetes who were subopitmally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 25967.
  • 2
    Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S. Liraglutide, a long acting human glucagon like peptide analogue, given as monotherapy significantly improves glycaemic control and lowers body weight in people with type 2 diabetes. Diabetes Care 2007; 30: 160810.
  • 3
    Buse JB, Rosenstock J, Sesti GG, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 3947.
  • 4
    Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R. Liraglutide versus insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes (LEAD 5-Met + SU) a randomised controlled trial. Diabetologia 2009; 52: 204655.
  • 5
    Gutzwiller JP, Tscopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon like peptide induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 305561.
  • 6
    Gardiner SM, March JE, Kemp PA, Bennett T. Mesenteric vasoconstriction and hindquarter vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006; 316: 8529.
  • 7
    Gardiner S, March J, Kemp P, Bennett T. Autonomic nervous system-dependent and independent cardiovascular effects of exendin-4 infusions in conscious rats. Br J Pharmacol 2008; 154: 6071.
  • 8
    Nikolaidis L, Mankad S, Sokos G, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon like peptide in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 9625.
  • 9
    Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 6949.
  • 10
    Jansen J, Screuder J, Wesseling K. A comparison of cardiac output derived from the arterial pressure wave against thermodilution in cardiac surgery patients. Br J Anaesth 2001; 87: 21222.
  • 11
    Schutte A, Huisman H, van Rooyen J, Malan N, Schutte R. Validation of the Finometer device for measurement of blood pressure in Black women. J Hum Hypertens 2004; 18: 7984.
  • 12
    Khoo E, Wallis J, Tsintzas K, Macdonald I, Mansell P. Effects of circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise. Diabetologia 2010; 53: 13943.
  • 13
    Kothare P, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, de la Peña A, Teng CH, Mace K, Fineman M, Shigeta H, Sakata Y, Irie S. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with Type 2 diabetes mellitus. J Clin Pharmacol 2008; 48: 138999.
  • 14
    Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994; 266: E45966.
  • 15
    Bojanowska E, Stempniak B. Effects of glucagon-like peptide-1 (7-36)amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat. J Endocr 2002; 172: 30310.
  • 16
    Klonoff D, Buse J, Nielsen L. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 27586.
  • 17
    Buse JB, Bergenstal RM, Glass LC. Use of twice daily exenatide in basal insulin treated patients with type 2 diabetes: a randomised controlled trial. Ann Intern Med 2011; 154: 10312.
  • 18
    Golpon HA, Peuchner A, Welte T, Wichert PV, Federsen CO. Vasorelaxant effect of glucagon-like peptide – (7-36) amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 816.
  • 19
    Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E120915.
  • 20
    Poornima I, Brown S, Bhashyam S, Parikh P, Bolukoglu H, Shannon R. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008; 1: 15360.
  • 21
    Basu A, Charkoudian N, Schrage W, Basu R, Joyner M. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide not glimepiride. Am J Physiol Endocrinol Metab 2007; 293: E128995.
  • 22
    Thraisndottir I, Malmberg K, Olsson A, Gutniak M, Ryde N. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004; 1: 403.
  • 23
    Best J, Hoogwerf B, Herman W. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the GLP-1 receptor agonist exenatide twice daily or other glucose lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011; 34: 905.
  • 24
    Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, Braun D, Giaconia J, Malone J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010; 9: 6.
  • 25
    Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 43647.
  • 26
    Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analogue liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 122430.
  • 27
    Holst JJ. The physiology of glucagon like peptide. Physiol Rev 2007; 87: 140939.
  • 28
    Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon like 1 receptor. Endocrinology 1996; 137: 2982978.
  • 29
    Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 234050.
  • 30
    Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesions by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 10307.
  • 31
    Nystrom T, Gonon A, Sjoholm A, Pernow J. Glucagon like peptide-1 relaxes rat conduit arteries via an endothelium independent mechanism. Regul Pept 2005; 125: 1737.
  • 32
    Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005; 289: H24018.
  • 33
    Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009; 380: 449.